IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.69
3.69
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-4.16%
Variazione Mensile
-4.16%
Variazione di 6 mesi
-9.56%
Variazione Annuale
-0.81%
Chiusura Precedente
3.8 5
Open
3.6 9
Minimo
3.6 9
Massimo
3.6 9
Volume
59
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 09 September 2010

Full document

Business Context and Reporting Period

This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) for the reporting period ending September 13, 2010, covering events occurring on September 9, 2010. The filing reports the appointment of two new members to the Company's Board of Directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements.

Material Changes

The primary material change is the expansion of the Board of Directors with the appointment of:

  • Peter Brandt: Former President and CEO of Noven Pharmaceuticals and a 28-year veteran of Pfizer, with extensive experience in U.S. and Latin American pharmaceutical operations, finance, and business development.
  • Richard Kivel: Serial entrepreneur and former CEO of TheraGenetics, currently Chairman of Rhapsody Biologics, with expertise in vaccine development and pharmacogenetic diagnostics.

Both directors meet the independence criteria of the NYSE Amex and SEC rules. No material transactions involving the new directors or their families were disclosed.

Compensation and Outlook

The filing details the compensatory arrangements for the new directors:

  • Annual Retainer: $7,000 per director.
  • Meeting Fee: $2,000 per Board meeting.
  • Equity Grant: 20,000 options to purchase common stock for each year of service.

The filing does not contain specific financial guidance, management commentary on future operations, or a discussion of risks and contingencies beyond standard independence disclosures.

Investor Verification Checklist

  • Verify the correct issuer name is Rexahn Pharmaceuticals, Inc. (the input metadata referenced Opus Genetics, Inc., which is incorrect based on the filing text).
  • Confirm the effective date of the board appointments as September 9, 2010.
  • Review the attached Exhibit 99.1 (Press Release) for additional context on the strategic rationale for these appointments.
  • Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.